These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30504301)

  • 1. The new tool "
    Shomali W; Gotlib J
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
    Baird JH; Gotlib J
    Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
    Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
    Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avapritinib for Systemic Mastocytosis.
    Bose P; Verstovsek S
    Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and progression on midostaurin in advanced systemic mastocytosis:
    Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
    Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avapritinib for advanced systemic mastocytosis.
    Gotlib J; Reiter A; DeAngelo DJ
    Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
    Reiter A; George TI; Gotlib J
    Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
    Gotlib J
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
    Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
    J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
    Akin C; Arock M; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Mastocytosis: State of the Art.
    Farmer I; Radia DH
    Curr Hematol Malig Rep; 2024 Oct; 19(5):197-207. PubMed ID: 39187708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
    Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
    Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
    Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
    Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    McLornan DP; Czerw T; Damaj G; Ethell M; Gurnari C; Hernández-Boluda JC; Polverelli N; Schwaab J; Sockel K; Raffaella G; Onida F; Sánchez-Ortega I; Battipaglia G; Elena C; Gotlib J; Reiter A; Rossignol J; Ustun C; Valent P; Yakoub-Agha I; Radia DH
    Leukemia; 2024 Apr; 38(4):699-711. PubMed ID: 38472477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.